draft proposal for amendments (combined) · draft proposal for amendments ... draft proposal for...

DRAFT PROPOSAL FOR AMENDMENTS

INDIAN PHARMACOPOEIA COMMISSION of 37

DRAFT PROPOSAL FOR AMENDMENTS (Combined)

2.4.13. Gas Chromatography. Page 193

Insert before Performance

Injection volume. Where no injection volume is specified in the monograph, the analyst should select an appropriate volume for their specific application. The volume chosen is dependent on the response of the analyte, the detector used, the efficiency of the column and the overall performance of the chromatographic system. Where a volume is not indicated, 1 µL is usually appropriate; however this should be checked for suitability under the local operating conditions. Secondary peaks. Reference may be made to a secondary peak. A secondary peak is a peak in the chromatogram other than the principal peak and any peaks due to internal standard, solvent and derivatising agents. Peaks identified as being due to the counter-ion and/or other excipients including preservatives in the material being examined may also be excluded.

2.4.14. Liquid Chromatography. Page 196

System suitability. Page 199

Insert after para 2

The following requirements and any supplementary requirements given in the individual monograph are to be fulfilled unless otherwise prescribed:

In a related substances test or assay, for a peak in the chromatogram obtained with a reference solution used for quantification, the symmetry factor is 0.8 to 1.5, unless otherwise prescribed,

In an assay of an active substance, where the value is 100 per cent for a pure substance, the maximum permitted relative standard deviation (sr (%) max) for the defined limits is calculated for a series of injections of the reference solution using the following equation:

��(%)max =�� √�

��%,��

where, K = constant (0.349), obtained from the expression K = �.�

√� x

��%,�

√� in which

�.�

√� represents

the required percentage relative standard deviation after six injections for B = 1.0, B = upper limit given in the definition of the individual monograph minus 100 per cent,

n = number of replicate injections of the reference solution (3 ≤ n ≤ 6),

t90%,n−1 = Student’s t at the 90 per cent probability level (double sided) with n−1 degrees of freedom.

Unless otherwise prescribed, the maximum permitted relative standard deviation does not exceed the appropriate value given in table 1 of repeatability requirements. This requirement does not apply to the tests for related substances. Table 1. Repeatability requirements

Number of Individual Injections

3 4 5 6

B(percent) 2.0 2.5 3.0

Maximum Permitted Relative Standard Deviation

0.41 0.52 0.62

0.59 0.74 0.89

0.73 0.92 1.10

0.85 1.06 1.27



In a related substances test, the limit of quantification (corresponding to a signal-to-noise ratio of 10) is

equal to or less than the disregard limit.

Compliance with the system suitability criteria is required throughout the chromatographic procedure. Depending on various factors, such as the frequency of use of the procedure and experience with the chromatographic system, the analyst chooses an appropriate verification scheme to monitor this.

Adjustment of chromatographic conditions. Page 200

Change to: Adjustment of chromatographic conditions

The extent to which the various parameters of a chromatographic test may be adjusted to satisfy the system suitability criteria without fundamentally modifying the methods are listed below. Adjustment of conditions with gradient elutions is more critical than with isocratic elutions, since it may lead to shifts in peaks to a different step of the gradient, thus leading to the incorrect assignment of peaks, and to the masking of peaks or a shift such that elution occurs beyond the prescribed elution time. Changes other than those indicated require revalidation of the method. The chromatographic conditions described have been validated during the elaboration of the monograph.

The system suitability tests are included to verify that the separation required for satisfactory performance of the test or assay is achieved. Nonetheless, since the stationary phases are described in a general way and there is such a variety available commercially, with differences in chromatographic behaviour, some adjustments of the chromatographic conditions may be necessary to achieve the prescribed system suitability requirements. With reversed-phase liquid chromatographic methods in particular, adjustment of the various parameters will not always result in satisfactory chromatography. In that case, it may be necessary to replace the column with always result in satisfactory chromatography. In that case, it may be necessary to replace the column with another of the same type (e.g. octadecylsilyl silica gel), which exhibits the desired chromatographic behaviour.

For critical parameters the adjustments are defined clearly in the monograph to ensure the system suitability.

Isocratic elution Composition of the mobile phase. The amount of the minor solvent component may be adjusted by ± 30 per cent relative or ± 2 per cent absolute, whichever is the larger; no other component is altered by more than 10 per cent absolute. pH of the aqueous component of the mobile phase. ± 0.2 pH, unless otherwise prescribed, or ± 1.0 pH when non-ionisable substances are to be examined. Concentration of salts in the buffer component of a mobile phase. ± 10 per cent. Flow rate. ± 50 per cent; a larger adjustment is acceptable when changing the column dimensions (see the formula below). Column parameters Stationary phase:

no change of the identity of the substituent of the stationary phase permitted (e.g. no replacement of C18 by C8),

particle size: maximum reduction of 50 per cent; no increase permitted.

Column dimensions: length: ± 70 per cent, internal diameter: ± 25 per cent.

When column dimensions are changed, the flow rate may be adjusted as necessary using the following equation:

�� = ��

�� 22

�� 12



F1 = flow rate indicated in the monograph, in millilitres per minute, F2 = adjusted flow rate, in millilitres per minute, l1 = length of the column indicated in the monograph, in millimetres,

l2 = length of the column used, in millimetres, d1 = internal diameter of the column indicated in the monograph, in millimetres, d2 = internal diameter of the column used, in millimetres. Temperature. ± 10 °, where the operating temperature is specified, unless otherwise prescribed. Detector wavelength. No adjustment permitted. Injection volume. May be adjusted as far as it is consistent with accepted precision, linearity, and detection limits. Note that excessive injection volume can lead to unacceptable band broadening, causing a reduction in column efficiency and resolution. Gradient elution Adjustment of chromatographic conditions for gradient systems requires greater caution than for isocratic systems. Composition of the mobile phase/gradient elution. Minor adjustments of the composition of the mobile phase and the gradient are acceptable provided that:

the system suitability requirements are fulfilled, the principal peak(s) elute(s) within ± 15 per cent of the indicated retention time(s), the final composition of the mobile phase is not weaker in elution power than the prescribed composition.

Where compliance with the system suitability requirements cannot be achieved, it is often preferable to consider the dwell volume or to change the column.

Dwell volume. The configuration of the equipment employed may significantly alter the resolution, retention time and relative retentions described. Should this occur, it may be due to excessive dwell volume. Monographs preferably include an isocratic step before the start of the gradient programme so that an adaptation can be made to the gradient time points to take account of differences in dwell volume between the systems used for method development and that actually used. It is the user's responsibility to adapt the length of the isocratic step to the analytical equipment used. If the dwell volume used during the elaboration of the monograph is given in the monograph, the time points (t min) stated in the gradient table may be replaced by adapted time points (tc min), calculated using the following equation:

�� = � − (� − �� )

�

D = dwell volume, in millilitres; D0 = dwell volume used for development of the method, in millilitres; F = flow rate, in millilitres per minute.

The isocratic step introduced for this purpose may be omitted if validation data for application of the method without this step is available.

pH of the aqueous component of the mobile phase. No adjustment permitted. Concentration of salts in the buffer component of a mobile phase. No adjustment permitted. Flow rate. Adjustment is acceptable when changing the column dimensions (see the formula below). Column parameters. Stationary phase:

no change of the identity of the substituent of the stationary phase permitted (e.g. no replacement of C18 by C8),



particle size: no adjustment permitted.

Column dimensions. length: ± 70 per cent, internal diameter: ± 25 per cent.

When column dimensions are changed, the flow rate may be adjusted as necessary using the following equation:

�� = ��

�� 22

�� 12

F1 = flow rate indicated in the monograph, in millilitres per minute, F2 = adjusted flow rate, in millilitres per minute, l1 = length of the column indicated in the monograph, in millimetres, l2 = length of the column used, in millimetres, d1 = internal diameter of the column indicated in the monograph, in millimetres, d2 = internal diameter of the column used, in millimetres. Temperature . ± 5°, where the operating temperature is specified, unless otherwise prescribed. Detector wavelength. No adjustment permitted. Injection volume. May be adjusted as far as it is consistent with accepted precision, linearity, and detection limits. Note that excessive injection volume can lead to unacceptable band broadening, causing a reduction in column efficiency and resolution. Fig. 2.4.14-1 is a graphical representation of the common events during chromatography and assists in understanding the various terms more commonly employed and discussed below.

2.4.15. Paper Chromatography. Page 202

Insert at the end Adjustment of chromatographic conditions Composition of the mobile phase. The amount of the minor solvent component may be adjusted by ± 30 per cent relative or ± 2 per cent absolute, whichever is the larger; for a minor component at 10 per cent of the mobile phase, a 30 per cent relative adjustment allows a range of 7-13 per cent whereas a 2 per cent absolute adjustment allows a range of 8-12 per cent, the relative value therefore being the larger; for a minor component at 5 per cent of the mobile phase, a 30 per cent relative adjustment allows a range of 3.5-6.5 per cent whereas a 2 per cent absolute adjustment allows a range of 3-7 per cent, the absolute value being the larger in this case; no other component is altered by more than 10 per cent absolute. pH of the aqueous component of the mobile phase. ± 0.2 pH, unless otherwise prescribed, or ± 1.0 pH when non-ionisable substances are to be examined. Concentration of salts in the buffer component of a mobile phase. ± 10 per cent. Application volume. 10-20 per cent of the prescribed volume if using fine particle size plates (2-10 µm).

2.4.17. Thin-Layer Chromatography. Page 204 Adjustment of chromatographic conditions. Page 205 pH of the aqueous component of the mobile phase. Lines 2 and 3 Change from: ± 0.1 pH, when neutral substances are to be examined; to: ± 1.0 pH, when non-ionisable substances are to be examined;

2.4.26. Solubility. Page 220 Mannitol. Page 237



Change to: Mannitol. Freely soluble in water, practically insoluble in ethanol (95 per cent).

2.4.26. Solubility. Page 220 Quetiapine Fumarate. Page 245 Change to: Slightly soluble in water, in ethanol and in methanol.

2.5.2. Dissolution Test. Page 302

Insert after para 4 For dosage forms containing or coated with gelatin that do not conform to the dissolution specification, repeat the test as follows.

Dissolution Medium with pH 4.0 or less Enzyme: Pepsin, activity determined by the procedure in pepsin. Amount: A quantity of pepsin that results in an activity of not more than 7,50,000 Units per litre of dissolution medium. Dissolution Medium with more than pH 4.0 and less than 6.8 Enzyme: Papain, activity determined by the Assay test in the monograph for Papain. Amount: A quantity of papain that results in an activity of not more than 5,50,000 Units per litre of dissolution medium. Dissolution Medium with pH 6.8 or more Enzyme: Pancreatin, protease activity determined by the procedure in Assay for protease activity in the monograph for Pancreatin. Amount: A quantity of pancreatin that results in a protease activity of not more than 2000 Units per litre of dissolution medium. NOTE- Appropriate organic solvent(s) may be used to enhance drug solubility for the preparation of the reference standard solutions. However, not more than 5 per cent (v/v) of the organic solvent should be present in the final solution unless validated. Apparatus 1 (Paddle Apparatus) Dissolution medium, para 2 Delete the requirement.

6.3. Closures for Containers. Page 1059

Identification. A Change to: A. Heat 1 g to 2 g of rubber stoppers in a heat resistant test tube over an open flame to dry the sample and continue heating until pyrolysate vapours are condensed near the top edge of the test tube. Deposit a few drops of the condensate on a potassium bromide disc and examine by infrared absorption spectrophotometry (2.4.6), comparing with the spectrum obtained with the type (specimen) sample. or Examine by Attenuated Total Reflectance [ATR] (2.4.6). The spectrum obtained is identical to the spectrum obtained with the type (specimen) sample. If necessary, cut the sample along an appropriate axis, examine the cut surface and compare the spectrum with that obtained with the type (specimen) sample prepared in the similar way.

Artesunate. Page 1267

Related substances Change to: Related substances. Determine by liquid chromatography (2.4.14). Test solution. Dissolve 40 mg of the substance under examination in acetonitrile and dilute to 10.0 ml with acetonitrile. Reference solution (a). Dilute 1.0 ml of the test solution to 100.0 ml with acetonitrile.



Reference solution (b). A solution containing 0.1 per cent w/v of artesunate RS and 0.01 per cent w/v each of artenimol RS and artemisinin RS in acetonitrile. Chromatographic system

a stainless steel column 10 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (3 μm), mobile phase: a mixture of 56 volumes of buffer solution prepared by dissolving 1.36 g of potassium

dihydrogen phosphate in 1000 ml of water, adjusted to pH 3.0 with orthophosphoric acid and 44 volumes of acetonitrile,

flow rate: 1 ml per minute, spectrophotometer set at 216 nm, injection volume: 20 μl.

Name Relative retention time

Artesunate impurity A (10-epi-artenimol)1 0.58 Artenimol 0.91 Artesunate (Retention time: about 9 minutes) 1.0 Artesunate impurity B (artemisinin)2 1.3 Artesunate impurity C (anhydrodihydroartemisinin)3 2.7

1(3R,5aS,6R,8aS,9R,12R,12aR)-3,6,9-trimethyldecahydro-12H-3,12-epoxypyrano[4,3-j]-1,2-benzodioxepin-10-ol(dihydroartemisinins: artenimol and (10R)-artenimol), 2(3R,5aS,6R,8aS,9R,12S,12aR)-3,6,9-trimethyloctahydro-3,12-epoxypyrano[4,3-j]-1,2-benzodioxepin-10(3H)-one (artemisinin), 3(3R,5aS,6R,8aS,12R,12aR)-3,6,9-trimethyl-3,4,5,5a,6,7,8,8a-octahydro-12H-3,12-epoxypyrano[4,3-j]-1,2-benzodioxepine (anhydrodihydroartemisinin).

Inject reference solution (b). The test is not valid unless the peak-to-valley ratio (Hp/Hv) is not less than 5.0, where Hp is the height above the baseline of the peak due to artenimol and Hv is the height above the baseline of the lowest point of the curve separating the peak due to artenimol from the peak due to artesunate. Inject reference solution (a) and the test solution. Run the chromatogram 4 times the retention time of the principal peak. In the chromatogram obtained with the test solution, the combined area of any peaks due to 10-epi-artenimol and artenimol (impurity A) is not more than the area of the principal peak in the chromatogram obtained with reference solution (a) (1.0 per cent), the area of any peak due to impurity B (artemisinin) is not more than 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.5 per cent), the area of any peak due to impurity C multiplied by correction factor 0.07, is not more than 0.2 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.2 per cent) and the area of any other secondary peak is not more than 0.2 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.2 per cent). The sum of the areas of all the secondary peaks is not more than twice the area of the principal peak in the chromatogram obtained with reference solution (a) (2.0 per cent). Ignore any peak with an area less than 0.05 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.05 per cent).

Aspirin Tablets. Page 1277 Change to: Aspirin Tablets

Acetylsalicylic Acid Tablets Aspirin Tablets contain not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of aspirin, C9H8O4. Usual strengths. 75 mg; 150 mg; 300 mg; 600 mg.

Identification Shake a quantity of powdered tablets containing 0.5 g Aspirin with 20.0 ml of ethanol, Filter. Evaporate the filtrate and dry the residue at 60° for 1 hour. The residues comply with the following test. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with aspirin RS or with the reference spectrum of aspirin.

Tests Dissolution (2.5.2). Apparatus No. 2,



Medium: 500 ml of buffer solution pH 4.5 prepared by dissolving 2.99 g of sodium acetate and 1.66 ml of glacial acetic acid with sufficient water and dilute to 1000 ml with water, Speed and time. 50 rpm for 45 minutes. Withdraw a suitable volume of the medium and filter. Dilute a suitable volume of the filtrate with the dissolution medium and measure the absorbance of the resulting solution at the maximum at about 265 nm (2.4.7). Calculate the content of C9H8O4 in the medium from the absorbance obtained from a solution of known concentration of aspirin RS in the same medium. D. Not less than 70 per cent of the stated amount of C9H8O4 Related substances. Determine by liquid chromatography (2.4.14), Note- Prepare the solutions immediately before use. Test solution. Disperse a quantity of the powdered tablets containing 0.1 g of Aspirin in 40 ml of acetonitrile with the aid of ultrasound for 15 minutes and dilute to 100.0 ml with water. Reference solution (a). Dilute 1.0 ml of the test solution to 50.0 ml with the mobile phase. Dilute 1.0 ml of the solution to 10.0 ml with the mobile phase. Reference solution (b). A 0.003 per cent w/v solution of salicylic acid (aspirin impurity C) in the mobile phase. Reference solution (c). Dilute 5.0 ml of reference solution (b) and 1.0 ml of the test solution to 10.0 ml with the mobile phase. Chromatographic system – a stainless steel column 25 cm x 4 mm, packed with octadecylsilane bonded to porous silica (5 µm), – mobile phase: a mixture of 40 volumes of acetonitrile, 60 volumes of water and 0.2 volume of

orthophosphoric acid, – flow rate: 1 ml per minute, – spectrophotometer set at 237 nm, – injection volume: 20 µl. Name Relative retention time (in minutes) Aspirin impurity A1 0.6 Aspirin impurity B2 0.7 Aspirin (Retention time: about 5 minutes) 1.0 Aspirin impurity C3 1.4 Aspirin impurity F4 8.0 14-hydroxybenzoic acid, 24-hydroxyisophthalic acid, 3salicylic acid, 4acetylsalicylic anhydride.

Inject reference solution (c). The test is not valid unless the resolution between the peaks due to aspirin and aspirin impurity C is not less than 6.0. Inject reference solution (a), (b) and the test solution. Run the chromatogram 1.2 times the retention time of aspirin impurity F. In the chromatogram obtained with the test solution, the area of any peak corresponding to aspirin impurity C is not more than the area of the principal peak in the chromatogram obtained with reference solution (b) (3.0 per cent), the area of any other secondary peak is not more than 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.1 per cent) and the sum of areas of all other secondary peaks is not more than 5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (1.0 per cent). Ignore any peak with an area less than 0.25 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.05 per cent). Other tests. Comply with the tests stated under Tablets.



Assay. Determine by liquid chromatography (2.4.14), using chromatographic system and reference solution (c) as described under Related substances. Note- Prepare the solutions immediately before use. Test solution. Weigh and powder 20 tablets. Disperse a quantity of the powder containing 60 mg of Aspirin in 40 ml of acetonitrile, with the aid of ultrasound for 15 minutes and dilute to 100.0 ml with water. Reference solution. A 0.06 per cent w/v solution of aspirin RS in the mobile phase. Inject reference solution (c). The test is not valid unless the resolution between the peaks due to aspirin and aspirin impurity C is not less than 6.0. Inject the reference solution and the test solution. Calculate the content of C9H8O4 in the tablets. Storage. Store protected from moisture, at a temperature not exceeding 30°. Labelling. The label states, if the tablets are dispersible should be dispersed in water immediately before use.

Soluble Aspirin Tablets. Page 1277

Change to: Soluble Aspirin Tablets

Soluble Acetylsalicylic Acid Tablets; Effervescent Soluble Aspirin Tablets; Effervescent Aspirin Tablets; Calcium Aspirin Tablets. Soluble Aspirin Tablets contain Aspirin in a suitable soluble, effervescent base. Soluble Aspirin Tablets contain not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of aspirin, C9H8O4. Usual strengths. 300 mg.

Identification A. Shake a quantity of powdered tablets containing 0.5 g Aspirin with 20.0 ml of ethanol and filter. Evaporate the filtrate and dry the residue at 60° for 1 hour. The residues comply with the following test. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with aspirin RS or with the reference spectrum of aspirin. B. Dissolve with vigorous effervescence on the addition of warm water to produce a clear solution.

Tests

Related substances. Determine by liquid chromatography (2.4.14), Note- Prepare the solutions immediately before use. Test solution. Disperse a quantity of the powdered tablets containing 0.1 g of Aspirin in 40 ml of acetonitrile with the aid of ultrasound for 15 minutes and dilute to 100.0 ml with water. Reference solution (a). Dilute 1.0 ml of the test solution to 50.0 ml with the mobile phase. Dilute 1.0 ml of the solution to 10.0 ml with the mobile phase. Reference solution (b). A 0.003 per cent w/v solution of salicylic acid (aspirin impurity C) in the mobile phase. Reference solution (c). Dilute 5.0 ml of reference solution (b) and 1.0 ml of the test solution to 10.0 ml with the mobile phase.



Chromatographic system – a stainless steel column 25 cm x 4 mm, packed with octadecylsilane bonded to porous silica (5 µm), – mobile phase: a mixture of 40 volumes of acetonitrile, 60 volumes of water and 0.2 volume of

orthophosphoric acid, – flow rate: 1 ml per minute, – spectrophotometer set at 237 nm, – injection volume: 20 µl. Name Retention time (in minutes) Aspirin impurity A1 0.6 Aspirin impurity B2 0.7 Aspirin (Retention time: about 5 minutes) 1.0 Aspirin impurity C3 1.4 Aspirin impurity F4 8.0 14-hydroxybenzoic acid, 24-hydroxyisophthalic acid, 3salicylic acid, 4acetylsalicylic anhydride.

Inject reference solution (c). The test is not valid unless the resolution between the peaks due to aspirin and aspirin impurity C is not less than 6.0. Inject reference solution (a), (b) and the test solution. Run the chromatogram 1.2 times the retention time of aspirin impurity F. In the chromatogram obtained with the test solution, the area of any peak corresponding to aspirin impurity C is not more than the area of the principal peak in the chromatogram obtained with reference solution (b) (3.0 per cent), the area of any other secondary peak is not more than 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.1 per cent) and the sum of areas of all other secondary peaks is not more than 5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (1.0 per cent). Ignore any peak with an area less than 0.25 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.05 per cent). Other tests. Comply with the tests stated under Tablets. Assay. Determine by liquid chromatography (2.4.14), using chromatographic system and reference solution (c) as described under Related substances. Note- Prepare the solutions immediately before use. Test solution. Weigh and powder 20 tablets. Disperse a quantity of the powder containing 60 mg of Aspirin in 40 ml of acetonitrile, with the aid of ultrasound for 15 minutes and dilute to 100.0 ml with water. Reference solution. A 0.06 per cent w/v solution of aspirin RS in the mobile phase. Inject reference solution (c). The test is not valid unless the resolution between the peaks due to aspirin and aspirin impurity C is not less than 6.0. Inject the reference solution and the test solution. Calculate the content of C9H8O4 in the tablets. Storage. Store protected from moisture, at a temperature not exceeding 30°.

Bisacodyl Gastro-resistant Tablets. Page 1390 Related substances Change to: Related substances. Determine by liquid chromatography (2.4.14). Solvent mixture. 4 volumes of glacial acetic acid, 30 volumes of acetonitrile and 66 volumes of water.



Test solution. Shake a quantity of the powdered tablets containing about 25 mg of Bisacodyl with 40 ml of the solvent mixture and dilute to 50.0 ml with the same solvent, filter. Reference solution (a). Dilute 1.0 ml of the test solution to 100.0 ml with the solvent mixture. Reference solution (b). Dilute 1.0 ml of reference solution (a) to 10.0 ml with the solvent mixture. Chromatographic system

- a stainless steel column 25 cm x 4.6 mm, packed with base deactivated octadecylsilane bonded to porous silica (5µm),

-mobile phase: a mixture of 45 volumes of acetonitrile and 55 volumes of 0.025 M ammonium formate, previously adjusted to pH 5.0 with anhydrous formic acid,

- flow rate: 1.5 ml per minute, - spectrophotometer set at 265 nm, - injection volume: 50 µl

Name Relative Correction retention time factor

Bisacodyl impurity A1 0.2 0.7 Bisacodyl impurity B2 0.4 - Bisacodyl impurity C3 0.45 - Bisacodyl impurity D4 0.8 - Bisacodyl impurity E5 0.9 - Bisacodyl (Retention time : about 13 minutes) 1.0 - Bisacodyl impurity F6 2.6 -

14,4′-(pyridin-2-ylmethylene)diphenol 22-[(RS)-(4-hydroxyphenyl)(pyridin-2-yl)methyl]phenol, 34-[(RS)-(4-hydroxyphenyl)(pyridin-2-yl)methyl]phenyl acetate, 4, 6unknown structure. 52-[(RS)-[4-(acetyloxy) phenyl](pyridin-2-yl)methyl]phenyl acetate,

Inject reference solution (a), (b) and the test solution. Run the chromatogram 3.5 times of the retention time of the principal peak. In the chromatogram obtained with the test solution, the area of any secondary peak corresponding to bisacodyl impurity C is not more than 1.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (1.5 per cent), the area of any secondary peak corresponding to bisacodyl impurity A is not more than 0.8 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.8 per cent), the area of any secondary peak corresponding to bisacodyl impurity E is not more than 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.5 per cent), the area of any secondary peak corresponding to bisacodyl impurity F is not more than 0.3 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.3 per cent), the area of any secondary peak corresponding to bisacodyl impurity D is not more than 0.2 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.2 per cent), the area of any other secondary peak is not more than the area of the principal peak in the chromatogram obtained with reference solution (b) (0.1 per cent) and the sum of areas of all the secondary peaks excluding bisacodyl impurity A and C is not more than 5 times of the area of the principal peak in the chromatogram obtained with reference solution (b) (0.5 per cent). Ignore any peak with an area less than 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.05 per cent).

Brinzolamide. Page 1404 Related substances Change to: Limit of Brinzolamide Related Compound A Test solution. Dissolve about 25 mg of the substance under examination in ethanol and dilute to 50.0 ml with ethanol.



Reference solution. A solution containing 0.04 per cent w/v of brinzolamide RS and 0.002 per cent w/v of brinzolamide impurity A RS (S-(-)-4-ethylamino-2, 3-dihydro-2-(-3-methoxypropyl)-4H-thieno-[3,2,e]-thiazine-6-sulphonamide-1,1-dioxide ) in ethanol. Chromatographic system - a stainless steel column 25 cm x 4.6 mm, such as chiral Pack ADH (5 μm), - mobile phase: a mixture of 55 volumes of ethanol, 40 volumes of hexane, 5 volumes of methanol and 0.2 volume of diethylamine, - flow rate: 0.75 ml per minute, - spectrophotometer set at 254 nm, - injection volume: 5 μl. The relative retention time with reference to brinzolamide for brinzolamide impurity A is about 1.2. Inject the reference solution. The test is not valid unless the resolution between brinzolamide and brinzolamide impurity A is not less than 1.8, the column efficiency is not less than 2000 theoretical plates and tailing factor is not more than 1.8 for the brinzolamide peak. Inject the test solution. The area of any peak due to brinzolamide impurity A is not more than 0.5 per cent, calculated by area normalization. Related substances. Determine by liquid chromatography (2.4.14). Test solution. Dissolve 50 mg of the substance under examination in the mobile phase A and dilute to 50.0 ml with mobile phase A. Reference solution. A solution containing 0.01 per cent w/v each of brinzolamide RS and brinzolamide impurity B RS ((R)-4-Amino-2-(3-methoxypropyl)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulphonamide 1,1-dioxide oxalate in mobile phase A. Chromatographic system - a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm), - mobile phase: A. a mixture of 75 volumes of buffer solution prepared by dissolving 4.0 ml of triethylamine in 1000 ml of water adjusted to pH 3.0 with orthophosphoric acid and 25 volumes of acetonitrile, B. a mixture of 65 volumes of buffer solution prepared by dissolving 4.0 ml of triethylamine in 1000 ml of water adjusted to pH 3.0 with orthophosphoric acid and 35 volumes of acetonitrile, - flow rate: 1 ml per minute, - spectrophotometer set at 230 nm, - injection volume: 10 µl. The relative retention time with reference to brinzolamide for brinzolamide impurity B is about 0.8 using mobile phase A. Inject the reference solution. The test is not valid unless the resolution between brinzolamide and brinzolamide impurity B is not less than 2.0, the column efficiency is not less than 2000 theoretical plates and tailing factor is not more than 2.0 for the brinzolamide peak. Analysis 1 Inject the test solution using mobile phase A. Run the chromatogram for about 20 minutes. The area of any secondary peak is not more than 0.3 per cent, calculated by area normalization. Analysis 2 Inject the test solution using mobile phase B. Run the chromatogram for about 20 minutes and measure the areas for brinzolamide and all the peaks having a relative retention not less than 6. The area of any secondary peak is not more than 0.3 per cent and the sum of areas of all secondary peaks is not more than 1.0 per cent, calculated by area normalization from analysis1 and analysis 2.



Cefpodoxime Tablets. Page 1536 Labelling Insert at the end If the tablets are dispersible, the tablets should be dispersed in water immediately before use.

Chloroquine Phosphate. Page 1587

Identification A. Para 2

Insert at the end

“or with the reference spectrum of chloroquine.”

Chloroquine Phosphate Injection. Page 1588


Insert at the end


Chloroquine Phosphate Suspension. Page 1589

Identification. Para 2

Insert at the end


Chloroquine Phosphate Tablets. Page 1589


Insert at the end


Chloroquine Sulphate. Page 1590


Insert at the end


Chloroquine Sulphate Injection. Page 1591


Insert at the end


Chloroquine Sulphate Tablets. Page 1592


Insert at the end


Assay. Line 9

Change from: 0.0436 g

to: 0.0209 g

Chloroquine Syrup. Page 1593

Identification. Para 2

Insert at the end




Clonazepam. Page 1669

Identification

Insert at the end

“or with the reference spectrum of Clonazepam.”

Dextran 40 Injection. Page 1787

Change to: Dextran 40 Infusion

Dextran 40 Injection; Dextran 40 Intravenous Infusion

Dextran 40 Infusion is a sterile solution containing Dextran 40 in Dextrose Injection or in Sodium Chloride Injection.

Dextran 40 Infusion contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of dextran 40. Description. An almost colourless, slightly viscous solution.

Tests Acidity. Titrate 25.0 ml of infusion with 0.01 M sodium hydroxide using phenol red solution as indicator. Not more than 2.0 ml of 0.01 M sodium hydroxide is required to neutralise the solution. Molecular size. For solutions in Dextrose Injection, before proceeding with tests A, B and C add 4 volumes of ethanol (95 per cent), centrifuge and dissolve the residue in a volume of Sodium Chloride Injection sufficient to restore the original volume. A. Determine the viscosity (2.4.28) ratios by Method A, using size C U-tube viscometer at 37°, of solutions in saline solution containing about 3.5, 2.5, 1.5 and 0.75 per cent w/v of dextrans, accurately determined. Calculate the viscosity ratio by dividing the time taken for the meniscus to fall from E to F using the liquid being examined by the time taken using saline solution. For each solution, plot (viscosity ratio – 1.00)/concentration (in per cent w/v) against concentration (in per cent w/v). The intercept on the viscosity axis of the straight line joining the points represents the intrinsic viscosity. The intrinsic viscosity is 0.16 to 0.20. B. Place in each of five stoppered flasks 100 ml of a solution in saline solution containing 6 per cent w/v of dextrans and add slowly, with continuous stirring, sufficient ethanol to produce a faint cloudiness (about 45 ml is usually required). Add 0.5, 1.0, 1.5, 2.0 and 2.5 ml of ethanol to the separate flasks, stopper the flasks and immerse in a water-bath at about 35° with occasional shaking until clear solutions are obtained. Transfer the flasks to a water-bath maintained at 25.0° ± 0.1° and allow to stand overnight or until two clear liquid phases are formed. Reject the supernatant liquids, dissolve separately the syrupy residues in sufficient saline solution to produce 25.0 ml, remove the ethanol by evaporation at a pressure of about 2 kPa, dilute to 25.0 ml with water and determine the optical rotation (2.4.22). From the optical rotations calculate the amount of dextrans precipitated as described in the Assay. Choose that fraction containing as nearly as possible but not more than 10 per cent of the dextrans present in the injection and determine its intrinsic viscosity by the method described under test A; the intrinsic viscosity is not more than 0.27. C. Place in each of four stoppered flasks 100 ml of a solution in saline solution containing 6 per cent w/v of dextrans and add slowly, with continuous stirring, 80, 90, 100 and 110 ml respectively of ethanol. Stopper the flasks, transfer to a water-bath maintained at 25.0° ± 0.1° and allow standing overnight or until two clear liquid phases are formed. Separate the supernatant solution from the syrupy residues. Remove the ethanol from each supernatant solution separately by evaporation at a pressure of 2 kPa, dialyse in cellophane tubing against water to remove sodium chloride, adjust the volume to 25.0 ml with water, add sufficient sodium chloride to produce solutions containing 0.9 per cent w/v and determine the optical rotation (2.4.22). From the optical rotations, calculate the amounts of dextrans present as described in the Assay. Choose that fraction containing as nearly as possible but not more than



10 per cent of the dextrans present in the injection and determine the intrinsic viscosity by the method in test A above; the intrinsic viscosity is not less than 0.08. Content of dextrose (if present). 4.5 per cent to 5.5 per cent w/v.

Dilute 15.0 ml of infusion to 50.0 ml with water. To 5.0 ml in a stoppered flask, add 25 ml of a buffer solution containing 14.3 per cent w/v of sodium carbonate and 4.0 per cent w/v of potassium iodide and 25.0 ml of 0.05 M iodine. Stopper the flask and allow to stand for exactly 30 minutes at 20°, add 35 ml of 2 M hydrochloric acid and titrate immediately with 0.1 M sodium thiosulphate. Repeat the operation using 5 ml of water, beginning at the words “add 25 ml of a buffer solution...”. The difference between the titrations represents the amount of the iodine required to oxidise the dextrose. 1 ml of 0.05 M iodine is equivalent to a 0.00901 g of dextrose. Content of sodium chloride (if present). 0.81 per cent to 0.99 per cent w/v. To a measured volume containing 0.09 g of sodium chloride, titrate with 0.1 M silver nitrate using potassium chromate solution as indicator. 1 ml of 0.1 M silver nitrate is equivalent to 0.005844 g of NaCl. Bacterial endotoxins (2.2.3). Not more than 1.25 Endotoxin Units per ml. Other tests. Comply with the tests stated under Parenteral Preparations (Infusions). Assay. For solutions in Dextrose Injection — Add 0.05 ml of 5 M ammonia to the required volume and measure the optical rotation (2.4.22). Calculate the content of dextrans from the following expression,

0.5076(α - 0.528D)

where α is the observed angular rotation and D the content of dextrose per cent w/v, determined in the test for Content of dextrose. For solutions in Sodium Chloride Injection — Measure the optical rotation (2.4.22), and multiply the value obtained, by 0.5076. Storage. Store at a temperature not exceeding 30°. The injection should not be exposed to undue fluctuations of temperature. Labelling. The label states (1) the strength as the percentage w/v of dextrans; (2) the name of the solvent; (3) that the injection should not be used if it is cloudy or if a deposit is present.

Dextran 70 Injection. Page 1788

Change to: Dextran 70 Infusion

Dextran 70 Injection; Dextran 70 Intravenous Infusion Dextran 70 Infusion is a sterile solution containing Dextran 70 in Dextrose Injection or in Sodium Chloride Injection.

Dextran 70 Infusion contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of dextran 70. Description. An almost colourless, slightly viscous solution.

Tests Acidity. Titrate 25.0 ml of infusion with 0.01 M sodium hydroxide using phenol red solution as indicator. Not more than 1.25 ml of 0.01 M sodium hydroxide is required to neutralise the solution.



Molecular size. For solutions in Dextrose Injection, before proceeding with tests A, B and C add 4 volumes of ethanol (95 per cent), centrifuge and dissolve the residue in a volume of Sodium Chloride Injection sufficient to restore the original volume. A. Determine the viscosity (2.4.28) ratios by Method A, using size C U-tube viscometer at 37°, of solutions in saline solution containing about 3.5, 2.5, 1.5 and 0.75 per cent w/v of dextrans, accurately determined. Calculate the viscosity ratio by dividing the time taken for the meniscus to fall from E to F using the liquid being examined by the time taken using saline solution. For each solution, plot (viscosity ratio – 1.00)/concentration (in per cent w/v) against concentration (in per cent w/v). The intercept on the viscosity axis of the straight line joining the points represents the intrinsic viscosity. The intrinsic viscosity is 0.22 to 0.27. B. Place in each of five stoppered flasks 100 ml of a solution in saline solution containing 6 per cent w/v of dextrans and add slowly, with continuous stirring, sufficient ethanol to produce a faint cloudiness (about 45 ml is usually required). Add 0.5, 1.0, 1.5, 2.0 and 2.5 ml of ethanol to the separate flasks, stopper the flasks and immerse in a water-bath at about 35° with occasional shaking until clear solutions are obtained. Transfer the flasks to a water-bath maintained at 25.0° ± 0.1° and allow to stand overnight or until two clear liquid phases are formed. Reject the supernatant liquids, dissolve separately the syrupy residues in sufficient saline solution to produce 25.0 ml, remove the ethanol by evaporation at a pressure of about 2 kPa, dilute to 25.0 ml with water and determine the optical rotation (2.4.22). From the optical rotations calculate the amount of dextrans precipitated as described in the Assay. Choose that fraction containing as nearly as possible but not more than 10 per cent of the dextrans present in the injection and determine its intrinsic viscosity by the method described under test A; the intrinsic viscosity is not more than 0.36. C. Place in each of four stoppered flasks 100 ml of a solution in saline solution containing 6 per cent w/v of dextrans and add slowly, with continuous stirring, 80, 90, 100 and 110 ml respectively of ethanol. Stopper the flasks, transfer to a water `bath maintained at 25.0° ± 0.1° and allow standing overnight or until two clear liquid phases are formed. Separate the supernatant solution from the syrupy residues. Remove the ethanol from each supernatant solution separately by evaporation at a pressure of 2 kPa, dialyse in cellophane tubing against water to remove sodium chloride, adjust the volume to 25.0 ml with water, add sufficient sodium chloride to produce solutions containing 0.9 per cent w/v and determine the optical rotation (2.4.22). From the optical rotations, calculate the amounts of dextrans present as described in the Assay. Choose that fraction containing as nearly as possible but not more than 10 per cent of the dextrans present in the injection and determine the intrinsic viscosity by the method in test A above; the intrinsic viscosity is not less than 0.13. Content of dextrose (if present). 4.5 per cent to 5.5 per cent w/v.

Dilute 15.0 ml of infusion to 50.0 ml with water. To 5.0 ml in a stoppered flask, add 25 ml of a buffer solution containing 14.3 per cent w/v of sodium carbonate and 4.0 per cent w/v of potassium iodide and 25.0 ml of 0.05 M iodine. Stopper the flask and allow to stand for exactly 30 minutes at 20°, add 35 ml of 2 M hydrochloric acid and titrate immediately with 0.1 M sodium thiosulphate. Repeat the operation using 5 ml of water, beginning at the words “add 25 ml of a buffer solution...”. The difference between the titrations represents the amount of the iodine required to oxidise the dextrose. 1 ml of 0.05 M iodine is equivalent to a 0.00901 g of dextrose. Content of sodium chloride (if present). 0.81 per cent to 0.99 per cent w/v. To a measured volume containing 0.09 g of sodium chloride, titrate with 0.1 M silver nitrate using potassium chromate solution as indicator. 1 ml of 0.1 M silver nitrate is equivalent to 0.005844 g of NaCl. Bacterial endotoxins (2.2.3). Not more than 1.21 Endotoxin Units per ml. Other tests. Comply with the tests stated under Parenteral Preparations (Infusions). Assay. For solutions in Dextrose Injection — Add 0.05 ml of 5 M ammonia to the required volume and measure the optical rotation (2.4.22). Calculate the content of dextrans from the following expression,

0.5076(α - 0.528D)



where α is the observed angular rotation and D the content of dextrose per cent w/v, determined in the test for Content of dextrose. For solutions in Sodium Chloride Injection — Measure the optical rotation (2.4.22), and multiply the value obtained, by 0.5076. Storage. Store at a temperature not exceeding 30°. The injection should not be exposed to undue fluctuations of temperature. Labelling. The label states (1) the strength as the percentage w/v of dextrans; (2) the name of the solvent; (3) that the injection should not be used if it is cloudy or if a deposit is present.

Diltiazem Hydrochloride

Change to: Diltiazem Hydrochloride

O

O

SN

O

O

N

H

Cl C22H26N2O4S,HCl Mol. Wt. 451.0 Diltiazem Hydrochloride is (2S,3S)-2,3,4,5-tetrahydro-5-(2-dimethylaminoethyl)-2-(4-methoxyphenyl)-4-oxobenzo[b]thiazepin-3-yl acetate hydrochloride.

Diltiazem Hydrochloride contains not less than 98.5 per cent and not more than 101.5 per cent of C22H26N2O4S,HCl, calculated on the dried basis.

Category. Antianginal; (calcium-channel blocker).

Dose. Initially, 30 to 60 mg thrice daily; maximum, 480 mg daily.

Description. A white, crystalline powder or small crystals.

Identification

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with diltiazem hydrochloride RS or with the reference spectrum of diltiazem hydrochloride.

B. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the principal peak in the chromatogram obtained with reference solution (a).

C. A 5 per cent w/v solution gives the reactions of chlorides (2.3.1).

Tests

Specific optical rotation (2.4.22). +110.0° to +116.0°, determined in a 1.0 per cent w/v solution.

Related substances. Determine by liquid chromatography (2.4.14).

Test solution. Dissolve 0.12 g of the substance under examination in methanol and dilute 100.0 ml with methanol.

Reference solution (a). A 0.12 per cent w/v solution of diltiazem hydrochloride RS in methanol.

Reference solution (b). A solution containing 0.0012 per cent w/v each of diltiazem hydrochloride RS and desacetyl diltiazem hydrochloride RS in methanol.

Chromatographic system – a stainless steel column 30 cm x 3.9 mm, packed with octadecylsilane bonded to porous silica (5 µm), – mobile phase: a mixture of 50 volumes of a buffer solution containing 0.116 per cent w/v of d-10-

camphorsulphonic acid in 0.1 M sodium acetate, adjusted to pH 6.2 with 0.1 M sodium hydroxide, 25 volumes of acetonitrile and 25 volumes of methanol,

– flow rate: 1.6 ml per minute, – spectrophotometer set at 240 nm,



– injection volume: 10 µl. The relative retention time with reference to diltiazem for desacetyl diltiazem is about 0.65. Inject reference solution (b). The test is not valid unless the resolution between the peaks due to desacetyl diltiazem and diltiazem is not less than 3 and the column efficiency is not less than 1200 theoretical plates and relative standard deviation for replicate injections is not more than 10.0 per cent for diltiazem peak. Inject reference solution (b) and the test solution. In the chromatogram obtained with the test solution, the area of any peak corresponding to desacetyl diltiazem is not more than 0.5 times the area of the corresponding peak in the chromatogram obtained with reference solution (b) (0.5 per cent). The area of any other secondary peak is not more than 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.5 per cent). The sum of the areas of all the secondary peaks is not more than the area of the principal peak in the chromatogram obtained with reference solution (b) (1.0 per cent). Heavy metals (2.3.13). 1.0 g complies with the limit test for heavy metals. Method A (20 ppm).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105° for 2 hours.

Assay. Determine by liquid chromatography (2.4.14) as given under Related substances using the following modifications.

Inject reference solution (a). The test is not valid unless the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject reference solution (a) and the test solution.

Calculate the content of C22H26N2O4S,HCl.

Storage. Store protected from light.

Diltiazem Injection. Page 1843 Insert before Other tests Related substances. Determine by liquid chromatography (2.4.14).

Test solution. Dilute a volume of injection containing 0.12 g of the diltiazem hydrochloride to 100.0 ml with methanol.

Reference solution (a). A 0.12 per cent w/v solution of diltiazem hydrochloride RS in methanol.

Reference solution (b). A solution containing 0.0012 per cent w/v each of diltiazem hydrochloride RS and desacetyl diltiazem hydrochloride RS in methanol.

Chromatographic system – a stainless steel column 30 cm x 3.9 mm, packed with octadecylsilane bonded to porous silica (5 µm), – mobile phase: a mixture of 50 volumes of a buffer solution containing 0.116 per cent w/v of d-10-

camphorsulphonic acid in 0.1 M sodium acetate, adjusted to pH 6.2 with 0.1 M sodium hydroxide, 25 volumes of acetonitrile and 25 volumes of methanol,

– flow rate: 1.6 ml per minute, – spectrophotometer set at 240 nm, – injection volume: 10 µl. The relative retention time with reference to diltiazem for desacetyl diltiazem is about 0.65. Inject reference solution (b). The test is not valid unless the resolution between the peaks due to desacetyl diltiazem and diltiazem is not less than 3 and the column efficiency is not less than 1200 theoretical plates and relative standard deviation for replicate injections is not more than 10.0 per cent for diltiazem peak. Inject reference solution (b) and the test solution. In the chromatogram obtained with the test solution, the area of any peak corresponding to desacetyl diltiazem is not more than 0.5 times the area of the corresponding peak in the chromatogram obtained with reference solution (b) (0.5 per cent). The area of any other secondary peak is not more



than 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.5 per cent). The sum of the areas of all the secondary peaks is not more than the area of the principal peak in the chromatogram obtained with reference solution (b) (1.0 per cent).

Diltiazem Tablets. Page 1843 Insert before Other tests

Related substances. Determine by liquid chromatography (2.4.14).

Solvent mixture. 40 volumes of acetonitrile and 60 volumes of water.

Test solution. Disperse a quantity of the powdered tablets containing 50 mg of diltiazem hydrochloride in the solvent mixture with the aid of ultrasound for 60 minutes and dilute to 100.0 ml with the solvent mixture. Centrifuge the solution for 20 minutes and use the supernatant.

Reference solution. A solution containing 0.00025 per cent w/v each of diltiazem hydrochloride RS and desacetyl diltiazem hydrochloride RS in the solvent mixture.

Chromatographic system

– a stainless steel column 15 cm x 2.1 mm, packed with octadecylsilane bonded to silica (1.7 µm), – mobile phase: A. a buffer solution prepared by dissolving 0.79 g of ammonium bicarbonate in 900 ml of

water, adjusted pH to 8.0 with ammonia solution and dilute to 1000 ml with water, B. acetonitrile, – a gradient programme using the conditions given below, – flow rate: 0.3 ml per minute, – spectrophotometer set at 240 nm, – injection volume: 2 µl.

Time Mobile phase A Mobile phase B (in min.) (per cent v/v) (per cent v/v)

0 95 5

2 95 5

5 60 40

13 60 40

16 30 70

20 30 70

20.1 95 5

25 95 5


Diltiazem impurity H1 0.44

Diltiazem impurity G2 0.52

Diltiazem impurity C3 0.58

Diltiazem impurity D4 0.61

Diltiazem impurity E5 0.66

Desacetyl diltiazem 0.75

Diltiazem impurity A6 0.83

Diltiazem impurity B7 0.89

Diltiazem 1.0 Note- These are impurities related to the drug substances. They are not to be reported for the drug product and should not be included in the total impurities. 1(2S,3S)-5-(2-Aminoethyl)-3-hydroxy-2-(4-hydroxyphenyl)-2,3-dihydro-1,5-benzothiazepine-4(5H)-one, 2(2S,3S)-3-Hydroxy-2-(3-methoxyphenyl)-5-[2-(methylamino)ethyl]-2,3-dihydrobenzo[b][1,4]thiazepin-4(5H)-one, 3(2S,3S)-5-[2-(Dimethylamino)ethyl]-2-(4-hydroxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate, 4(2S,3S)-2-(4-Methoxyphenyl)-5-[2-(methylamino)ethyl]-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepine-3-yl acetate, 5(2S,3S)-3-Hydroxy-2-(4-methoxyphenyl)-2,3-dihydro-1,5-benzothiazepine-4(5H)-one, 6(2R,3S)-5-[2-(Dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepine-3-yl acetate,



7(2S,3S)-2-(4-Methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepine-3-yl acetate.

Inject the reference solution. The test is not valid unless the resolution between the peaks due to desacetyl diltiazem and diltiazem is not less than 2. The relative standard deviation for each of the peak due to diltiazem hydrochloride and desacetyl diltiazem is not more than 3.0 per cent. Inject the reference solution and the test solution. In the chromatogram obtained with the test solution, the area of any peak corresponding to desacetyl diltiazem is not more than 3 times the area of corresponding peak in the chromatogram obtained with the reference solution (1.5 per cent). The area of any other secondary peak is not more than 0.4 times the area of principal peak in the chromatogram obtained with the reference solution (0.2 per cent). The sum of the areas of all the secondary peaks is not more than 4 times the area of the principal peak in the chromatogram obtained with the reference solution (2.0 per cent). Ignore any peak with an area less than 0.1 times the area of the principal peak in the chromatogram obtained with the reference solution (0.05 per cent).

Emtricitabine. Page 1936 Specific optical rotation Change from: -125.0° to -150.0°, determined in a 0.5 per cent w/v solution in methanol.

to: -105.0° to -115.0°, determined in a 0.25 per cent w/v solution in water. Enantiomeric purity Last para Change from: Calculate the content of the 5-fluoro-1-(2R,5S)-[2-(hydroxyl methyl)-1,3-oxathiolan-5-y1] cytosine isomer by area normalization, not more than 1.0 per cent. to: Calculate the content of the 5-fluoro-1-(2S,5R)-[2-(hydroxymethyl)-1,3-oxathiolan-5-y1] cytosine isomer by area normalization, not more than 0.3 per cent.

Hydrochlorothiazide Tablets. Page 2220

Assay Change to: Assay. Determine by liquid chromatography (2.4.14). Test solution. Weigh and powder 20 tablets. Disperse a quantity of the powder containing 30 mg of hydrochlorothiazide in 20 ml of the mobile phase with the aid of ultrasound, add 20 ml of acetonitrile and further sonicate for 5 minutes, with intermittent shaking and dilute to 200.0 ml with the mobile phase, filter. Reference solution (a). A 0.015 per cent w/v solution of hydrochlorothiazide RS in the mobile phase. Reference solution (b). A solution containing 0.015 per cent w/v each of hydrochlorothiazide RS and chlorothiazide RS in the mobile phase. Chromatographic system

a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm), mobile phase: a mixture of 90 volumes of 0.1M monobasic sodium phosphate and 10 volumes of

acetonitrile, adjusted to pH 3.0 with orthophosphoric acid, flow rate: 2 ml per minute, spectrophotometer set at 254 nm, injection volume: 20 µl.

The relative retention time for chlorothiazide with respect to hydrochlorothiazide is about 0.8, Inject the reference solution (a) and (b). The test is not valid unless the resolution between the peaks due to hydrochlorothiazide and chlorothiazide is not less than 2.0, in the chromatogram obtained with reference solution (b) and relative standard deviation for replicate injections is not more than 1.5 per cent in the chromatogram obtained with reference solution (a). Inject reference solution (a) and the test solution. Calculate the content of C7H8CIN3O4S2 in the tablets.



Hyoscine Butylbromide. Page 2246 Related substances Change to: Related substances. Determine by liquid chromatography (2.4.14). Test solution. Dissolve 50 mg of the substance under examination in mobile phase B and dilute to 10.0 ml with mobile phase B. Reference solution (a). Dilute 1.0 ml of the test solution to 100.0 ml with mobile phase B. Dilute 1.0 ml of the solution to 10.0 ml with mobile phase B. Reference solution (b). Dissolve 5 mg of hyoscine butylbromide for system suitability RS (containing impurity A and B) in mobile phase B and dilute to 10.0 ml with mobile phase B. Chromatographic system - a stainless steel column 10 cm x 4.6 mm, packed with silica gel bonded to alkyl groups (1.8 µm), - column temperature: 50°, - mobile phase A. a mixture of 5 volumes of acetonitrile and 95 volumes of a 0.2 per cent v/v solution of perchloric acid, B. a mixture of 30 volumes of a 0.2 per cent v/v solution of perchloric acid and 70 volumes of

acetonitrile, - a gradient programme using the conditions given below, - flow rate: 2.5 ml per minute, - spectrophotometer set at 210 nm, - injection volume: 2 µl. Time Mobile phase A Mobile phase B (in min.) (per cent v/v) (per cent v/v) 0 91 9 1 91 9 4.2 75 25 5.5 66 34 10 15 85 11 15 85 12 91 9


Bromide 0.1 Hyoscine impurity B1 0.32 Hyoscine impurity A2 0.37 Hyoscine butylbromide (Retention time: about 4.8 minutes) 1.0 1 (2RS)-3-hydroxy-2-phenylpropanoic acid (DL-tropic acid), 2 (1R,2R,4S,5S,7s)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl (2S)-3-hyroxy-2-phenylpropanoate (hyoscine).

Inject reference solution (b). The test is not valid unless the resolution between the peaks due to hyoscine impurity B and hyoscine impurity A is not less than 2.0.

Inject reference solution (a) and the test solution. In the chromatogram obtained with the test solution, the area of any peak corresponding to hyoscine impurity A is not more than 1.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.15 per cent), the area of any other secondary peak is not more than the area of the principal peak in the chromatogram obtained with reference solution (a) (0.1 per cent). The sum of the areas of all the secondary peaks is not more than 4 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.4 per cent). Ignore any peak with an area less than 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.05 per cent).



Irbesartan and Hydrochlorothiazide Tablets. Page 2311 Related substances Change to: Related substances. Determine by liquid chromatography (2.4.14), as described under Assay with the following modifications. Reference solution (c). Dilute 1.0 ml of reference solution (a) to 100.0 ml with the solvent mixture. Name Relative Correction retention time factor

Benzothiadiazine impurity A1 0.15 0.77 Hydrochlorothiazide 0.18 ---

Irbesartan impurity A2 0.86 --- Irbesartan 1.0 --- 14-amino-6-chloro-1,3-benzenedisulfonamide, 21-pentanoylamino-cyclopentanecarboxylic acid [2’-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amide. Inject reference solution (c) and the test solution. In the chromatogram obtained with the test solution, the area of any peak corresponding to irbesartan impurity A is not more than 0.3 times the area of the peak due to irbesartan in the chromatogram obtained with reference solution (c) (0.3 per cent), the area of any peak corresponding to benzothiadiazine impurity A is not more than 0.94 times the area of the peak due to hydrochlorothiazide in the chromatogram obtained with reference solution (c) (1.0 per cent) and the area of any other secondary peak is not more than 0.2 times the area of the peak due to irbesartan in the chromatogram obtained with reference solution (c) (0.2 per cent) and the sum of the areas of all the secondary peaks is not more than 1.5 times the area of the peak due to irbesartan in the chromatogram obtained with reference solution (c) (1.5 per cent).

Iron Dextran Injection. Page 2317

Change to: Iron Dextran Injection

Iron Dextran Injection is a sterile colloidal solution containing a complex of ferric hydroxide with practically hydrolised dextrans of average molecular weight about 1000.

Iron Dextran Injection contains not less than 95.0 per cent and not more than 105.0 per cent w/v of the stated amount of iron and not more than 0.5 per cent of phenol as a preservative.

Category. Haematinic.

Description. A dark brown slightly viscous liquid.

Identification

To 1 ml of Injection on a watch glass, add 2 drops of ammonium hydroxide. No precipitate is formed. Add 2 ml of hydrochloric acid, and 2 ml of ammonium hydroxide. A brown precipitate is formed.

Tests

pH (2.4.24). 4.5 to 7.0.

Chloride content. For products labelled to contain 50 mg per ml of iron: 0.48 per cent to 0.68 per cent; for products labeled to contain 75 or 100 mg per ml of iron: 0.8 per cent to 1.1 per cent.

To 10.0 ml of injection, add 50 ml of water and 2 ml of nitric acid and titrate immediately with 0.1 M silver nitrate, determining the end-point potentiometrically (2.4.25).

1 ml of 0.1 M silver nitrate is equivalent to 0.003545 g of Cl.

Phenol. Not more than 0.5 per cent,

Determine by gas chromatography (2.4.13).

Internal standard solution. A 0.2 per cent w/v soluion of benzyl alcohol in methanol.

Test solution. Mix 5.0 ml of injection and 10.0 ml of internal standard solution and dilute to 50.0 ml with water.



Reference solution (a). A 0.4 per cent w/v soluion of phenol.

Reference solution (b). Mix 5.0 ml of reference solution (a) and 10.0 ml of internal standard solution and dilute to 50.0 ml with water. Chromatographic system – a fused silica capillary column 30 m x 0.32 mm, packed with macrogol 20000 (film thickness 0.5 µm), – temperature: column- 150° for 5 minutes, 150° to 230° @ 10° per minute and hold at 230° for 7 minutes, – inlet port: 200° and detector. 310°, – flame ionization detector, – flow rate: 2 ml per minute, using nitrogen as the carrier gas, – injection volume: 1 µl, – split ratio: 10:1,

– run time: 20 minutes.

The relative retention time of benzyl alcohol with respect to phenol is about 0.85.

Inject reference solution (b). The test is not valid unless the resolution between the peaks due to benzyl alcohol and phenol is not less than 2.0, the tailing factor not more than 2.0 for the phenol peak and the relative standard deviation for replicate injections is not more than 1.0 per cent for the peak response ratio of phenol to benzyl alcohol.

Calculate the content of phenol (C6H6O) in the injection. Non-volatile Residue. For products labeled to contain 50 mg per ml of iron: 28.0 per cent to 32.0 per cent; 75 mg per ml of iron: 35.0 per cent to 40.0 per cent; 100 mg per ml of iron: 37.0 per cent to 43.0 per cent.

Transfer 1.0 ml of injection onto 3 to 5 g of sand spread in a shallow layer in a stainless steel dish, the dish and sand having been previously dried and weighed. Rinse the pipet, with several small portions of water, onto the sand. Evaporate on a steam bath to dryness, continue the drying in an oven at 105° for 15 hours, and weigh. Abnormal toxicity. Inject 0.10 ml into a tail vein of each of 10 mice; not more than 3 mice die within 5 days of injection. If more than 3 mice die within 5 days, repeat the test on another group of 20 mice. Not more than 10 of the 30 mice used in the combined tests die within 5 days of injection.

Bacterial endotoxins (2.2.3). Not more than 0.50 Endotoxin Unit per mg of iron.

Other tests. Comply with the tests stated under Parenteral Preparations (Injections).

Assay.

For iron - Determine by atomic absorption spectrophotometry (2.4.2), Method B.

Solvent mixture. Dissolve 2.64 g of calcium chloride dihydrate in 500 ml of water, add 5 ml of hydrochloric acid and dilute to 1000.0 ml with water.

Test solution. Dilute a volume of injection containing 100 mg of iron to 200.0 ml with the solvent mixture. Dilute

2.0 ml of the solution to 250.0 ml with the solvent mixture.

Reference solution. A solution of 50 µg per ml of iron prepared by dissolving 350 mg of ferrous ammonium sulphate

hexahydrate in 1000.0 ml of water. Dilute the solution to obtain the concentrations of 1 µg per ml, 2 µg per ml, 3 µg

per ml, 4 µg per ml and 5 µg per ml of iron in the solvent mixture.

Set the zero of the instrument using solvent mixture as blank. Measure the absorbance at 248.3 nm using a iron

hollow-cathode lamp as source of radiation and an air-acetylene flame.

Calculate the content of Iron, (Fe) in the injection.

Storage. Store at a temperature not exceeding 300, preserve in single dose and multi dose containers, preferably of Type I or Type II glass.

Labelling. The label states the strength in terms of the equivalent amount of iron, Fe, in a suitable dose-volume.



per cent.

Lamivudine and Zidovudine Tablets. Page 2381 Related substances. Last para Change to: Inject reference solution (a) and the test solution. In the chromatogram obtained with the test solution, the area of any peak corresponding to thymine is not more than 0.3 times the area of the principal peak in the chromatogram obtained with reference solution (a) (2.0 per cent). The area of any other secondary peak is not more than 0.5 per cent and sum of the areas of all the secondary peaks is not more than 3.0 per cent, calculated by area normalization. Ignore the peak due to zidovudine and any peak with a relative retention time of 0.11, 0.14, 0.2, 0.22, 0.6, 0.7, 0.8 and 1.1 as these impurities are process impurities.

Lamivudine, Nevirapine and Zidovudine Paediatric Dispersible Tablets. Page 2385 Related substances. Last para Insert at the end “Ignore the peaks due to nevirapine and zidovudine.”

Levetiracetam Oral Solution. Page 2409

Storage

Change from: Store protected from moisture. to: Store protected from light, at a temperature not exceeding 30º.

Mannitol. Page 2498

Change to: Mannitol D-Mannitol

HO

HO OH

HO OH

HO

C6H14O6 Mol. Wt. 182.2

Mannitol is D-mannitol, a hexahydric alcohol related to mannose. Mannitol contains not less than 97.0 per cent and not more than 102.0 per cent of C6H14O6, calculated on the dried

basis. Category. Osmotic diuretic; diagnostic aid (for renal function). Dose. As diuretic, by intravenous infusion, 50 to 200 g over 24 hours but not more than 50 g on one occasion preceded by a test dose of 200 mg per kg of body weight by slow intravenous injection; as diagnostic aid, by intravenous injection, 200 mg per kg of body weight in a 15 to 25 per cent w/v solution. Description. A white or almost white crystals or powder. It shows polymorphism (2.5.11). Identification Test A may be omitted if tests B, C and D are carried out. Tests B, C and D may be omitted if test A is carried out. A. Determine by infrared absorption spectrophotometery (2.4.6). Compare the spectrum with that obtained with mannitol RS or with the reference spectrum of mannitol. B. Melting point (2.4.21). See Test.



C. Specific optical rotation (2.4.22). +23.0° to +25.0°, determined in a solution prepared by dissolving 2.0 g of the substance under examination and 2.6 g of sodium tetraborate in 20 ml of water at 30° and shaking continuously for 15 to 30 minutes without further heating. Dilute the resulting clear solution to 25.0 ml with water. D. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G. Mobile phase. A mixture of 70 volumes of propanol, 20 volumes of ethyl acetate and 10 volumes of water. Test solution. Dissolve 25 mg of the substance under examination in water and dilute to 10.0 ml with the same solvent. Reference solution (a). A 0.25 per cent w/v solution of mannitol RS. Reference solution (b). A solution containing 0.25 per cent w/v each of mannitol RS and sorbitol RS. Apply to the plate 2 µl of each solution. After development, dry the plate in air, spray with 4-aminobenzoic acid solution, dry in cool air until the acetone is removed, heat it at 100° for 15 minutes allow to cool then spray it with a 0.2 per cent w/v solution of sodium periodate dry in cool air and heat at 100° for 15 minutes. The chromatogram shows two separated spots in the chromatogram obtained with reference solution (b). The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a).

Tests Appearance of solution. A 10.0 per cent w/v solution is clear (2.4.1), and colourless (2.4.1). Conductivity (2.4.9). Not more than 20 μS.cm-1, determined in a solution prepared by dissolving 20.0 gm of substance under examination in water by heating at 40° to 50° and dilute to 100.0 ml with the same solvent. Melting point (2.4.21). 165° to 170°. Nickel. Not more than 1 ppm. Determined by atomic absorption spectrophotometry (2.4.2), Method B. Test solution. Dissolve 20.0 g of the substance under examination in a mixture of equal volumes of dilute acetic acid and water and dilute to 100.0 ml with the same solvent. Add 2.0 ml of 1 per cent w/v solution of ammonium pyrrolidinedithiocarbamate and 10.0 ml of methyl isobutyl ketone and then shake for 30 seconds, protected from light. Allow the layers to separate and use the methyl isobutyl ketone layer. Reference solution. Prepare solution in the same manner as the test solution but adding 0.5 ml, 1.0 ml and 1.5 ml respectively of nickel standard solution (10 ppm Ni) in addition to the 20.0 g of the substance under examination. Set the zero of the instrument using methyl isobutyl ketone treated as described for preparation of the test solution omitting the substance under examination. Measure the absorbance at 232.0 nm using a nickel hollow-cathode lamp as source of radiation and an air-acetylene flame. Reducing sugars. Not more than 0.1 per cent (calculated as glucose equivalent). To 7.0 g, add 13 ml of water. Boil gently with 40 ml of cupri-tartaric solution for 3 minutes, and allow to stand for 2 minutes. A precipitate is formed. Filter through a sintered-glass filter. Wash the precipitate with hot water (about 50-60°) until the washing is no longer alkaline, and filter the washings through the same sintered-glass filter. Discard the filtrate. Immediately dissolve the precipitate in 20 ml of ferric sulfate solution, filter through the same sintered-glass filter, and wash the filter with 15-20 ml of water. Combine the washings and the filtrate, heat to 80°, and titrate with 0.02 M potassium permanganate. Not more than 3.2 ml is required to change the colour of the solution from green to pink so that the colour persists for at least 10 seconds. Related substances. Determine by liquid chromatography (2.4.14). Test solution. Dissolve 0.5 g of the substance under examination in 2.5 ml of water and dilute to 10.0 ml with the same solvent.



Reference solution (a). A 5.0 per cent w/v solution of mannitol RS with water. Reference solution (b). Dilute 2.0 ml of the test solution to 100.0 ml with water. Reference solution (c). Dilute 5.0 ml of reference solution (b) to 200.0 ml with water. Reference solution (d). A solution containing 2.5 per cent w/v each of mannitol RS and sorbitol RS (impurity A RS) in water. Reference solution (e). A solution containing 5.0 per cent w/v each of maltitol RS (impurity B) and isomalt RS (impurity C) in water. Dilute 2.0 ml of the solution to 10.0 ml with water. Chromatographic system – a stainless steel column 30 cm x 7.8 mm packed with strong cation-exchange resin (calcium form) (9 µm), – column temperature. 85 ± 2°,

– mobile phase: water, – flow rate: 0.5 ml per minute, – refractometer at constant temperature, – injection volume: 20 µl. The relative retention time with respect to mannitol for impurity C is about 0.6 (for first peak), impurity B is about 0.7, impurity C is about 0.73 (for second peak) and impurity A is about 1.2. (Impurity C elutes in two peaks. Coelution of impurity B and the second peak due to impurity C may be observed) Inject reference solution (d). The test is not valid unless the resolution between mannitol and impurity A is not less than 2. Inject reference solution (b), (c) and the test solution. In the chromatogram obtained with the test solution, the area of any peak corresponding to impurity A is not more than the area of the principal peak in the chromatogram obtained with reference solution (b) (2.0 per cent), the sum of areas of peaks corresponding to impurity B and C is not more than the area of the principal peak in the chromatogram obtained with reference solution (b) (2.0 per cent), the area of any other secondary peak is not more than twice the area of the principal peak in the chromatogram obtained with reference solution (c) (0.1 per cent) and the sum of the areas of all the secondary peaks is not more than the area of the principal peak in the chromatogram obtained with reference solution (b) (2.0 per cent). Ignore any peak with an area less than the area of the principal peak in the chromatogram obtained with reference solution (c) (0.05 per cent). Loss on drying (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105° for 4 hours. Assay. Determine by liquid chromatography (2.4.14) as described under Related substances with the following modification. Inject reference solution (a) and the test solution. Calculate the content of C6H14O6.

Mannitol intended for use in the manufacture of parenteral preparations without a further appropriate procedure for removal of bacterial endotoxins: Bacterial endotoxins (2.2.3). Not more than 4 Endotoxin Units per g for parenteral preparation having a concentration of 100 g per litre or less of mannitol, and not more than 2.5 Endotoxin Unit per g for parenteral preparations having a concentration of more than 100 g per litre of mannitol. Microbial contamination (2.2.9). Total aerobic microbial count is not more than 1000 CFU per g (100 CFU per g, if intended for use in manufacture of parenteral preparation) and total yeast and mold count is not more than 100 CFU per g. Test for absence of E coli and salmonella. Storage. Store protected from moisture.



Labelling. The label states where applicable, the maximum concentration of bacterial endotoxins; the substance is suitable for use in the manufacture of parenteral preparations.

Montelukast Sodium and Levocetirizine Hydrochloride Tablets. Page 2633 Related substances. Last para Insert at the end “Ignore the peak due to montelukast.”

Olanzapine Tablets. Page 2772 Insert before Other tests Uniformity of content. (For tablets containing 10 mg or less) complies with the test stated under Tablets. Determine by liquid chromatography (2.4.14), as described under Assay with the following modification. Test solution. Disperse one tablet in suitable volume of acetonitrile (25 per cent of the final volume) and dilute with 0.01 M hydrochloric acid to obtain a 0.01 per cent w/v solution of Olanzapine.

Olanzapine and Fluoxetine Tablets. Page 2773 Related substances. Last para Insert at the end “Ignore the peak due to fluoxetine.”

Oxaliplatin Injection. Page 2810

Oxalic Acid. Test solution

Change from: 0.2 per cent v/v

to: 0.2 per cent w/v

Related substances. Test solution

Change from: 0.2 per cent v/v

to: 0.2 per cent w/v

Phenytoin Oral Suspension. Page 2920 Para 1 Change to: Phenytoin Oral Suspension is a suspension of phenytoin in a suitable flavoured vehicle. Delete. Para 2 and 4 Storage Change to: Storage. Store at a temperature not exceeding 30°. Do not freeze. Delete before Identification “The constituted suspension complies with the tests stated under Oral Liquids and with the following tests.” Identification. Lines 1 and 2 Change from: Shake a quantity of the powdered tablets containing 0.1 g of Phenytoin Sodium with… to: Disperse a quantity of the suspension containing 0.1 g of Phenytoin with… Insert before Assay Other tests. Comply with the tests stated under Oral Liquids.

Piperacillin and Tazobactam Injection. Page 2939 Related substances Change to: Related substances. Determine by liquid chromatography (2.4.14).



NOTE- Use freshly prepared solutions, stored between 2° to 8° after preparation.

Solvent mixture A. 25 volumes of acetonitrile and 75 volumes of water.

Solvent mixture B. 4 volumes of acetonitrile and 96 volumes of solvent mixture A.

Test solution. Dissolve a sufficient quantity of injection in the mobile phase to obtain a solution containing 0.2 per cent w/v of piperacillin. Reference solution (a). A 0.05 per cent w/v solution of tazobactam RS in solvent mixture A.

Reference solution (b). A 0.1 per cent w/v solution of piperacillin RS in solvent mixture B (NOTE-Dissolve first in acetonitrile, using about 4 per cent of the final volume, and dilute with solvent mixture B to volume). Reference solution (c). A solution containing 0.0006 per cent w/v of tazobactam related compound A RS and 0.0025 per cent w/v of tazobactam RS in solvent mixture A. Reference solution (d). Dilute reference solution (a) and (b) with the mobile phase to obtain a solution containing 0.0025 per cent w/v of tazobactam RS and 0.02 per cent w/v of piperacillin RS. Chromatographic system

- a stainless steel column 15 cm x 4.6 mm, packed with phenyl group bonded to porous silica (3 µm), - sample temperature: 5°, - mobile phase: a mixture of 75 volumes of a buffer solution prepared by dissolving 1 g of tetrabutylammonium

hydrogen sulphate in 1000 ml of water and 25 volumes of acetonitrile, adjusted to pH 3.8 with 25 per cent v/v of orthophosphoric acid,

- flow rate: 1 ml per minute, - spectrophotometer set at 210 nm, - injection volume: 20 µl.

Name Relative Correction retention time factor

Tazobactam related compound A1 0.12 1.33 Tazobactam 0.25 - Piperacillin impurity B2 0.31 - Piperacillinpenilloic acid 3,4 0.36 - Piperacillinpenicilloic acid4,5 0.51 1.79 Acetylated penicilloic acid of piperacillin6 0.55 - Piperacillin impurity C 0.62 - Piperacillin impurity D 0.67 - Piperacillin 1.0 - 1(2S ,3S )-2-Amino-3-methyl-3-sulfino-4-(1H - 1;2,3-triazol-1 -y1)butyric acid, 2Specified unknown impurities, 3This compound has two epimers that usually co -elute but that may be separated as a result of minor changes in the chromatographic conditions, 4(4S )-2- { [2-(4-Ethyl-2,3-dioxopiperazine-1-carboxamido)-2-phenylacetamido]methy1}-5,5-dimethylthiazolidine-4-carboxylic acid, 5(2R ,4S )-2-{(1R )-Carboxy[2-(4-ethy1-2,3-dioxopiperazine-1-carboxamido)-2-phenylacetamido]methyI}-5,5-dimethylthiazolidine- 4-carboxylic acid, 6(2R ,4S )-3-Acetyl-2-{(1R )-carboxy[2-(4-ethyl-2,3-dioxopiperazine-1-carboxamido)-2-phenylacetamido]methyl}-5,5-dimethylthiazolidine-4-carboxylic acid,

Inject reference solution (c) and (d). The test is not valid unless the resolution between tazobactam related compound A and tazobactam peak is not less than 3.0 in the chromatogram obtained with reference solution (c), the tailing factor for tazobactam and piperacillin peak is not more than 1.8 and the relative standard deviation for replicate injections is not more than 2.0 per cent for each component in the chromatogram obtained with reference solution (d). Inject reference solution (d) and the test solution. In the chromatogram obtained with the test solution the area of any peak corresponding to tazobactam related compound A, piperacillin penilloic acid, piperacillin impurity B, C, D and acetylated penicilloic acid of piperacillin, each of, is not more than 0.1 times the area of the piperacillin peak in the chromatogram obtained with reference solution (d) (1.0 per cent), the area of any peak corresponding to piperacillin

INDIAN PHARMACOPOEIA COMMISSION

penicilloic acid is not more than 0.5 times the area of the piperacillin peak in the chromatogram obtained with reference solution (d) (5.0 per cent), the area of any other secopiperacillin peak in the chromatogram obtained with reference solution (d)all the secondary peaks other than piperacillinpiperacillin peak in the chromatogram obtained with reference solution (d)

Quetiapine Fumarate. P

Change to: Quetiapine Fumarate

C46H54N6O8S2

Quetiapine Fumarate is Bis[2-[2-[4-enedioate. Quetiapine Fumarate contains not less than 99.0 per cent and not more C46H54N6O8S2, calculated on the dried basis.

Category. Antipsychotic.

Description. A White or almost white powder

Identification Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with quetiapine fumarate RS or with the reference spectrum of

Tests Fumaric acid. 12.5 to 13.8 per cent.Dissolve 0.35 g of the substance under examination in water. Titrate with 0.1 M sodium hydroxide, blank titration. 1 ml of 0.1 M sodium hydroxide is equivalent to 0.0058 Related substances. Determine by liquid chromatography (2.4.14). Solvent mixture. Equal volumes of acetonitrile Test solution. Dissolve 50 mg of the substance under examination the solvent mixture. Reference solution. Dilute 1.0 ml of the test solution to 100.0solution to 10.0 ml with the solvent mixture. Chromatographic system

– a stainless steel column 10 cm x 2.1 mm, packed with endphenylhexylsilyl bonded to porous silica (1.7 µm),

– column temperature: 50˚,


INDIAN PHARMACOPOEIA COMMISSION

penicilloic acid is not more than 0.5 times the area of the piperacillin peak in the chromatogram obtained with (5.0 per cent), the area of any other secondary peak is not more than 0.1 ti

in the chromatogram obtained with reference solution (d) (1.0 per cent) all the secondary peaks other than piperacillin penicilloic acid peak is not more than 0.5 times the area of the piperacillin peak in the chromatogram obtained with reference solution (d) (5.0 per cent).

Page 3053

Quetiapine Fumarate

-(dibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl]ethoxy]ethanol] (2

contains not less than 99.0 per cent and not more calculated on the dried basis.

White or almost white powder. It shows polymorphism (2.5.11).

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with or with the reference spectrum of quetiapine fumarate.

per cent. of the substance under examination in 70 ml of a mixture of equal volume

0.1 M sodium hydroxide, determining the end-point potentiometrically (2.4.25). Carry out a

is equivalent to 0.005804 g of C4H4O4.

. Determine by liquid chromatography (2.4.14).

acetonitrile and water.

Dissolve 50 mg of the substance under examination in the solvent mixture and dilute to

ml of the test solution to 100.0 ml with the solvent mixture. Dilute 1solution to 10.0 ml with the solvent mixture.

less steel column 10 cm x 2.1 mm, packed with end-capped, charged surface, ethylenephenylhexylsilyl bonded to porous silica (1.7 µm),



penicilloic acid is not more than 0.5 times the area of the piperacillin peak in the chromatogram obtained with ndary peak is not more than 0.1 times the area of the

and the sum of the areas of than 0.5 times the area of the

Mol. Wt. 883.1

yl]ethoxy]ethanol] (2E)-but-2-

contains not less than 99.0 per cent and not more than 101.0 per cent of

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with

70 ml of a mixture of equal volumes of methanol and point potentiometrically (2.4.25). Carry out a

solvent mixture and dilute to 25.0 ml with

ml with the solvent mixture. Dilute 1.0 ml of the

capped, charged surface, ethylene-bridged



– mobile phase: A. a mixture of 90 volumes of buffer solution prepared by dissolving 3.85 g of ammonium acetate in 1000 ml of water, adjusted to pH 9.0 with ammonia solution and 10 volumes of methanol,

B. acetonitrile, – flow rate: 0.5 ml per minute, – a gradient programme using the conditions given below, – spectrophotometer set at 240 nm,

– injection volume: 3 l.

Time (in min.)

Mobile phase A (per cent v/v)

Mobile phase B (per cent v/v)

0 80 20 8 80 20

14.5 60 40 22.6 50 50 26 30 70 29 10 90 30 31 35

10 80 80

90 20 20

Name Relative retention time Correction factor

Fumaric acid 0.05 - Quetiapine impurity G1 0.5 0.5 Quetiapine (Retention time: 1 - about 13 minutes)

Quetiapine impurity N2 1.04 2.0 1 dibenzo[b,f][1,4]thiazepin-11(10H)-one, 2 2-[2-[4-[2-[2-[4-(dibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl]ethoxy]ethyl]piperazin-1-yl]ethoxy]ethanol,

Inject the reference solution. The test is not valid unless the signal-to-noise ratio for the principal peak is not less than 40. Inject the reference solution and the test solution. In the chromatogram obtained with test solution, the area of any peak corresponding to each of impurity G and impurity N is not more than 1.5 times the area of the principal peak in the chromatogram obtained with the reference solution (0.15 per cent); the area of any other secondary peak is not more than the area of the principal peak in the chromatogram obtained with the reference solution (0.1 per cent). The sum of areas of all the secondary peaks is not more than 5 times the area of the principal peak in the chromatogram obtained with the reference solution (0.5 per cent). Ignore any peak with an area less than 0.5 times the area of the principal peak in the chromatogram obtained with the reference solution (0.05 per cent). Ignore the peak due to fumaric acid. Sulphated ash (2.3.18). Not more than 0.1 per cent. Loss on drying (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in oven at 105˚. Assay. Dissolve 0.17 g of the substance under examination in 40 ml of glacial acetic acid. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.4.25). Carry out a blank titration. 1 ml of 0.1 M perchloric acid is equivalent to 0.02208 g of C46H54N6O8S2. Storage. Store protected from light.

Quetiapine Tablets. Page 3054

Change to: Quetiapine Tablets Quetiapine Fumarate Tablets



Quetiapine Tablets contain quetiapine fumarate equivalent to not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of quetiapine, C21H25N3O2S. Usual strengths. 25 mg; 50 mg; 100 mg; 200 mg; 300 mg.

Identification Shake a quantity of the powdered tablets containing the equivalent of 40 mg of quetiapine with 10 ml of acetonitrile, filter and discard the filtrate. Extract the residue with 10 ml of methanol, filter and evaporate the filtrate to dryness. On the residue, determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with quetiapine fumarate RS or with the reference spectrum of quetiapine fumarate.

Tests Dissolution (2.5.2). Apparatus No. 1, Medium. 900 ml of 0.01 M hydrochloric acid, Speed and time. 50 rpm and 30 minutes. Withdraw a suitable volume of the medium and filter. Measure the absorbance of the filtrate, suitably diluted with the dissolution medium if necessary, at the maximum at about 290 nm (2.4.7). Calculate the content of C21H25N3O2S in the medium from the absorbance obtained from a solution of 0.0032 per cent w/v of quetiapine fumarate RS in the same medium. D. Not less than 75 per cent of the stated amount of C21H25N3O2S. Related substances. Determine by liquid chromatography (2.4.14). Test solution. Disperse a quantity of the powdered tablets containing 25 mg of quetiapine in 20 ml of the mobile phase, with the aid of ultrasound and dilute to 25.0 ml with the mobile phase and filter. Reference solution (a). Dilute 1.0 ml of the test solution to 100.0 ml with the mobile phase. Dilute 1.0 ml of the solution to 5.0 ml with the mobile phase. Reference solution (b). A solution containing 0.02 per cent w/v of quetiapine fumarate RS and 0.004 per cent w/v of quetiapine impurity I RS in the mobile phase. Chromatographic system

– a stainless steel column 25 cm x 4.6 mm, packed with octylsilane bonded to porous silica (5 µm), – mobile phase: 7 volumes of acetonitrile, 39 volumes of a 0.26 per cent w/v solution of diammonium

hydrogen orthophosphate in water and 54 volumes of methanol. flow rate: 1.3 ml per minute, a gradient programme using the conditions given below, spectrophotometer set at 230 nm, injection volume: 30 l.

Name Relative Retention Time Correction factor

Quetiapine impurity H1 0.5 -

Quetiapine impurity G2 0.6 0.7

Quetiapine impurity I3 0.9 -

Quetiapine (retention time: about 14 minutes) 1.0 - 1 2-[2-[4-(dibenzo[b,f][1,4]thiazepin-11-yl)-1-oxidopiperazin-1-yl]ethoxy]ethanol, 2 dibenzo[b,f][1,4]thiazepin-11(10H)-one, 3 2-[4-(dibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl]ethanol,



Inject reference solution (b). The test is not valid unless the resolution between the peaks due to quetiapine and quetiapine impurity I is not less than 2.0.

Inject reference solution (a) and the test solution. Run the chromatogram twice the retention time of the principal peak for test solution. The area of any secondary peak is not more than the area of the principal peak in the chromatogram obtained with reference solution (a) (0.2 per cent). The sum of the areas of all the secondary peaks is not more than 5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (1.0 per cent). Ignore any peak with an area less than 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.1 per cent).

Other tests. Comply with the tests stated under Tablets. Assay. Determine by liquid chromatography (2.4.14), using chromatographic system and reference solution (b) as described under Related substances. Test solution. Weigh and powder 20 tablets. Disperse a quantity of powder containing 50 mg of quetiapine in 200 ml of the mobile phase, dilute to 250.0 ml with the mobile phase and filter. Reference solution (a). A 0.023 per cent w/v of quetiapine fumarate in the mobile phase. Inject reference solution (b). The test is not valid unless the resolution between the peaks due to quetiapine and quetiapine impurity I is not less than 2.0. Inject the reference solution and test solution. Calculate the content of C21H25N3O2S in the tablets. Each mg of quetiapine fumarate C46H54N6O8S2 is equivalent to 0.8686 mg of quetiapine, C21H25N3O2S. Storage. Store protected from moisture, at a temperature not exceeding 30˚. Labelling. The label states the strength in terms of the equivalent amount of quetiapine.

Quinapril and Hydrochlorothiazide Tablets. Page 3057 Related substances Change to: Related substances. Determine by liquid chromatography (2.4.14).

Solvent mixture. Equal volumes of mobile phase A and mobile phase B.

Test solution. Disperse a quantity of the powder containing 62.5 mg of hydrochlorothiazide in 50 ml of the solvent mixture, with the aid of ultrasound for 10 minutes. Add 50 ml of acetonitrile, mix with the aid of ultrasound for 15 minutes with occasional shaking and dilute to 250.0 ml with the solvent mixture.

Reference solution. A solution containing 0.005 per cent w/v each of quinapril hydrochloride RS, quinapril related compound A RS, quinapril related compound B RS, hydrochlorothiazide RS and benzothiadiazine related compound A RS in the solvent mixture. Dilute 1.0 ml of the solution to 100.0 ml with the solvent mixture.

Chromatographic system – a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm), – column temperature: 35°, – sample temperature: 5°, – mobile phase: A. a buffer solution prepared by dissolving 1.36 g of monobasic potassium phosphate in 1000

ml of water, add 2.0 ml of triethylamine, adjusted to pH 3.0 with orthophosphoric acid, B. acetonitrile, – flow rate: 1 ml per minute, – a gradient programme using the conditions given below, – spectrophotometer set at 215 nm, – injection volume: 20 µl.

Time Mobile phase A Mobile phase B



(in min.) (per cent v/v) (per cent v/v)

0 90 10

10 60 40

30 30 70

31 90 10

40 90 10


Benzothiadiazine related compound A1 0.42

Chlorothiazide2 0.45

Hydrochlorothiazide2 0.49

5-Chlorohydrochlorothiazide2 0.65

Quinapril related compound B3 0.74

Hydrochlorothiazide dimer2 0.78

Quinapril methyl ester2 0.91

Quinapril2 1.0

Quinapril isopropyl ester2 1.10

Hexahydroquinapril2 1.23

Quinapril related compound A4 1.59

Quinapril, benzyl ester2 1.94 14-Amino-6-chloro-1,3-benzenedisulfonamide,

2Process related impurity, monitored in the drug substance,

33-Isoquinolinecarboxylic acid, 2-[2-[(1-carboxy-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydro-, [3S-[2[R*(R*)],3R*]]],

4Ethyl[3S-[2(R*),3a,11a beta]]-1,3,4,6,11,11a-hexahydro-3-methyl-1,4-dioxo-alpha-(2-phenylethyl)-2H -pyrazino[1,2-b]isoquinoline-2-acetate,

Inject the reference solution. The test is not valid unless the column efficiency is not less than 5000 theoretical plates, the tailing factor is not more than 2.0 and the relative standard deviation of replicate injections is not more than 5.0 per cent for the peaks due to quinapril and hydrochlorothiazide.

Inject the reference solution and the test solution. In the chromatogram obtained with the test solution, the area of any peak corresponding to benzothiadiazine related compound A is not more than 5 times the area of the peak due to benzothiadiazine related compound A in the chromatogram obtained with the reference solution (1.0 per cent), the area of any peak corresponding to quinapril related compound A is not more than 5 times the area of the peak due to quinapril related compound A in the chromatogram obtained with the reference solution (1.0 per cent), the area of any peak corresponding to quinapril related compound B is not more than 15 times the area of the peak due to quinapril related compound B in the chromatogram obtained with the reference solution (3.0 per cent), the area of any other secondary peak is not more than the area of the peak due to quinapril in the chromatogram obtained with the reference solution (0.2 per cent). The sum of areas of all the secondary peaks other than quinapril related compound B and benzothiadiazine related compound A is not more than 10 times the area of the peak due to quinapril in the chromatogram obtained with the reference solution (2.0 per cent).

Ranitidine Oral Solution. Page 3097

Related substances

Change to: Related substances. Determine by liquid chromatography (2.4.14).

Buffer solution. Dissolve 6.804 g of potassium dihydrogen orthophosphate in 950 ml of water, adjusted to pH 7.1

with sodium hydroxide solution and dilute to 1000.0 ml with water

Test solution. Prepare a solid phase extraction cartridge containing a C18 sorbent (Such as Sep-Pak C18 cartridges) by

passing 10.0 ml of methanol followed by 20.0 ml of 0.5 M ammonia through the cartridge; attach the tip of a

suitable syringe to the cartridge. Transfer a weighed quantity of the oral solution containing the equivalent of 15 mg



of ranitidine to the barrel of the syringe, add 2.0 ml of 0.5 M ammonia to the syringe, insert the plunger and slowly

force the mixture through the cartridge, discarding the eluant; repeat with two 4.0 ml quantities of 0.5 M ammonia

discarding the eluant. Pass two 5.0 ml quantities of a mixture of 25 volumes of 0.1M hydrochloric acid and 75

volumes of methanol through the cartridge and collect the eluant; add 40.0 ml of ethanol to the collected eluant,

evaporate the resulting solution to dryness at a temperature not exceeding 30º under reduced pressure and dissolve

the residue in 2.0 ml of water.

Reference solution (a). Dilute 1.0 volume of the test solution to 50.0 volumes with water.

Reference solution (b). Dilute 1.0 volume of the test solution to 100.0 volumes with water.

Reference solution (c). Dilute 1.0 volume of the test solution to 200.0 volumes with water.

Reference solution (d). Dilute 1.0 volume of reference solution (b) to 5.0 volumes with water.

Reference solution (e). Dissolve the content of a vial of ranitidine impurity J RS in 1.0 ml of a solution containing

0.15 per cent w/v of ranitidine hydrochloride RS in water.

Chromatographic system − a stainless steel column 10 cm x 4.6 mm, packed with octadecylsilane amorphous organosilica polymer (3.5µm) (Such as XTerra MS C18), − column temperature: 35°, − mobile phase: A. a mixture of 2 volumes of acetonitrile and 98 volumes of buffer solution, B. a mixture of 22 volumes of acetonitrile and 78 volumes of buffer solution, − flow rate: 1.5 ml per minute, − a gradient programme using the conditions given below, − Spectrophotometer set at 230 nm, − injection volume: 20 µl.

Time Mobile phase A Mobile phase B

(in min.) (per cent v/v) (per cent v/v)

0 100 0

10 0 100

15 0 100

16 100 0

20 100 0

Inject reference solution (e). The test is not valid unless the resolution between two peaks corresponding to

ranitidine impurity J and ranitidine hydrochloride is not less than 1.5.

Inject reference solution (a), (b), (c), (d) and the test solution. In the chromatogram obtained with the test solution, the area of any secondary peak is not more than the area of principal peak in the chromatogram obtained with reference solution (a) (2.0 per cent). The area of not more than one secondary peak is more than the area of the principal peak in the chromatogram obtained with reference solution (b) (1.0 per cent). The area of not more than two other secondary peaks is more than the area of the principal peak in the chromatogram obtained with reference solution (c) (0.5 per cent). The area of not more than two further secondary peaks is not more than the area of the principal peak in the chromatogram obtained with reference solution (d) (0.2 per cent). The sum of the areas of all the secondary peaks is not more than 2.5 times the areas of the principal peak in the chromatogram obtained with reference solution (a) (5.0 per cent). Ignore any peak with an area less than 0.25 times the area of the principal peak in the chromatogram obtained with reference solution (d) (0.05 per cent).



Sorafenib Tosylate. Page 3242

Related substances

Insert at the end

Ignore any peak due to paratolulenesulphonic acid (relative retention time about 0.16).

Sorafenib Tablets. Page 3244

Related substances

Insert at the end

Ignore any peak due to paratolulenesulphonic acid (relative retention time about 0.16).

Tamsulosin Hydrochloride. Page 3306

Category

Change from: Uninary tract analgesic; antispasmodic.

to: Benign Prostatic Hyperplasia (BPH).

Thyroxine Sodium. Page 3370

Identification Change to: A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that

obtained with levothyroxine sodium RS or with the reference spectrum of levothyroxine sodium.

B. To 20 mg, add 2 ml of 1 M sulphuric acid. Heat on a water-bath followed by heating carefully over a naked flame, increasing the temperature to about 600°. Continue ignition until most of the black particles have disappeared. Dissolve the residue in 2 ml of water; the solution gives reaction (A) of sodium salts (2.3.1). Liothyronine Change to: Related substances. Determine by liquid chromatography (2.4.14). Solvent mixture. 30 volumes of mobile phase A and 60 volumes of ethanol (95 per cent), Test solution. Dissolve 25 mg of the substance under examination in the solvent mixture and dilute to 50.0 ml with the solvent mixture. Dilute 10.0 ml of the solution to 25.0 ml with the solvent mixture. Reference solution (a). A solution containing 0.0002 per cent w/v each of levothyroxine sodium RS and liothyronine sodium RS in the solvent mixture. Reference solution (b). Dilute 1.0 ml of reference solution (a) to 10.0 ml with the solvent mixture. Chromatographic system – a stainless steel column 15 cm x 4.0 mm, packed with end-capped octadecylsilane bonded to porous silica (3

µm), – mobile phase: A. 0.1 per cent w/v solution of orthophosphoric acid in water, B. 0.1 per cent w/v solution of orthophosphoric acid in acetonitrile, – a gradient programme using the conditions given below, – flow rate: 1 ml per minute, – spectrophotometer set at 225 nm, – injection volume: 25 µl.

Time Mobile phase A Mobile phase B (in min.) (per cent v/v) (per cent v/v)

0 70 30 10 70 30 40 20 80 50 20 80



55 70 30 Name Relative retention time Liothyronine1 0.5 levothyroxine ( retention time

about: 11 minutes) 1.0 levothyroxine impurity F2 2.0 levothyroxine impurity G3 2.4

1(2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoic acid (liothyronine), 2 (2S)-2-amino-3-[4-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenoxy]-3,5-diiodophenyl]propanoic acid, 3Unknown structure,

Inject reference solution (a). The test is not valid unless the resolution between the peaks due to levothyroxine and

liothyronine is not less than 5.0.

Inject reference solution (a), (b) and the test solution. In the chromatogram obtained with the test solution, the area of any peak corresponding to liothyronine is not more than the area of the corresponding peak of in the chromatogram obtained with reference solution (a) (1.0 per cent), the area of any peak corresponding to levothyroxine impurity F is not more than 5 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.5 per cent), the area of any peak corresponding to levothyroxine impurity G is not more than 3 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.3 per cent). The area of any other secondary peak is not more than twice the area of the principal peak in the chromatogram obtained with reference solution (b) (0.2 per cent). The sum of the all the impurities is not more than 2.0 per cent. Ignore any peak with an area less than 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.05 per cent). Loss of drying Change to: Water (2.3.43). 6.0 per cent to 12.0 per cent, determined on 0.1 g.

Thyroxine Tablets. Page 3371

Identification Change to: In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution.

Insert before Uniformity of content Dissolution (2.5.2). NOTE-All containers that are in contact with solutions containing levothyroxine sodium are to be made of glass. Apparatus No. 1, Medium. 500 ml of 0.2 per cent w/v solution of sodium lauryl sulphate in 0.01 M hydrochloric acid, Speed and time. 50 rpm and 45 minutes. Withdraw a suitable volume of the medium and filter. Determine by liquid chromatography (2.4.14). Test solution. Dilute the filtrate, if necessary, with the dissolution medium. Reference solution. A 0.01 per cent w/v solution of levothyroxine RS in methanol. Dilute suitably with the dissolution medium to obtain a solution of about the similar concentration as the test solution. Chromatographic system – a stainless steel column 25 cm x 4.6 mm, packed with nitrile groups chemically bonded to porous silica (5

µm),



– mobile phase: a mixture of 35 volumes of acetonitrile, 65 volumes of water and 0.05 volume of orthophosphoric acid,

– flow rate: 1.5 ml per minute, – spectrophotometer set at 225 nm, – injection volume: 100 µl. Inject the reference solution. The test is not valid unless the tailing factor is not more than 1.5 and the relative standard deviation for replicate injections is not more than 4.0 per cent. Inject the reference solution and the test solution. D. Not less than 80 per cent of the stated amount of C15H10 I4NNaO4 in the medium.

Liothyronine sodium. Determine by liquid chromatography (2.4.14). Solvent mixture. 60 volumes of methanol, 40 volumes of water and 0.05 volume of orthophosphoric acid. Solution A. Equal volumes of 0.02 M sodium hydroxide and methanol. Test solution. Disperse a quantity of powdered tablets containing 100 µg of levothyroxine sodium in 10.0 ml of the mobile phase, add 2 glass beads and mix on a vortex mixer for 3 minutes. Centrifuge and use the supernatant. Reference solution (a). A 0.04 per cent w/v solution of levothyroxine sodium RS in solution A. Reference solution (b). A 0.04 per cent w/v solution of liothyronine sodium RS in solution A. Dilute 1.0 ml of the solution to 100.0 ml with the mobile phase. Reference solution (c). Dilute 5.0 ml of reference solution (a) and 10.0 ml of reference solution (b) to 200.0 ml with the mobile phase. Reference solution (d). Dilute 1.0 ml of reference solution (b) to 20.0 ml with the mobile phase. Chromatographic system – a stainless steel column 25 cm x 4.6 mm, packed with nitrile groups chemically bonded to porous silica (5

µm), – mobile phase: 40 volumes of acetonitrile, 60 volumes of water and 0.05 volume of orthophosphoric acid, – flow rate: 1.5 ml per minute, – spectrophotometer set at 225 nm, – injection volume: 100 µl. Inject reference solution (c). The test is not valid unless the resolution between the peaks due to levothyroxine and liothyronine is not less than 5.0 and the relative standard deviation for replicate injections is not more than 2.0 per cent for levothyroxine peak. Inject reference solution (d) and the test solution. In the chromatogram obtained with the test solution, the area of any peak corresponding to liothyronine is not more than the area of the principal peak in the chromatogram obtained with reference solution (d) (2.0 per cent). Uniformity of content Test solution. Line 3 Change from: 0.0002 per cent

to: 0.000125 per cent

Reference solution. Line 1 Change from: 0.02 per cent

to: 0.0125 per cent

Sterile Water for Injections. Page 3518



Heavy metals. Delete the requirement Insert before Chlorides Conductivity (2.4.9). Meets the requirements of the test.

Carbimazole Tablets. Page 4429

Unifmority of content.

Test solution. Line 1

Change from: Disperse one tablet in 10.0 ml of acetonitrile with the aid of ultrasound for 5 minutes, filter. Dilute

1.0 ml of this solution to 10.0 ml with mobile phase A.

to: Disperse one tablet in 5 ml of water, with the aid of ultrasound for 5 minutes and dilute to 25.0 ml

with acetonetrile, filter. Dilute 5.0 ml of the solution to 20.0 ml with mobile phase A.

Assay.

Test solution.

Change from: Disperse a quantity of the powdered tablets containing 20 mg of Carbimazole in 10.0 ml of

acetonetrile with the aid of ultrasound for 5 minutes, filter. Dilute 5.0 ml of this solution to 200.0 ml

with mobile phase A.

to: Weigh and powder 20 tablets. Disperse a quantity of powder containing 20 mg of Carbimazole in 5 ml of

water, with the aid of ultrasound for 5 minutes and dilute to 20.0 ml with acetonetrile, filter. Dilute 5.0 ml of the

solution to 100.0 ml with mobile phase A.

Folic Acid and Methylcobalamin Tablets. Page 4448

Dissolution. Reference solution (c)

Change to: Reference solution (c). Dilute a suitable volume of reference solution (a) and reference solution (b) with

water to obtain a concentration similar to the test solution.

Sodium Alendronate Tablets. Page 4506

Para 2

Change from: Sodium Alendronate Tablets contain not less than 95.0 per cent and not more than 105.0 per cent of

the stated amount of , C4H13NO7P2.

to: Sodium Alendronate Tablets contain sodium alendronate equivalent to not less than 95.0 per cent and not

more than 105.0 per cent of the stated amount of alendronic acid , C4H3NO7P2.

Tazobactam Sodium. Page 4519

Identification A. Lines 2 and 3

Change from: tazobactam RS or with the reference spectrum of tazobactam.

to: tazobactam sodium RS or with the reference spectrum of tazobactam sodium.

draft proposal for amendments (combined) · draft proposal for amendments ... draft proposal for...

Documents